Bisphosphonates: Prevention of Bone Metastases in Lung Cancer
- 3 January 2012
- book chapter
- Published by Springer Nature
- Vol. 192, 93-108
Abstract
In patients with lung cancer, bone is one of the most frequent sites of distant spread, with approximately 30% of patients developing skeletal metastases. About half of these patients will experience a skeletal-related event, the occurrence of which not only affects quality of life, but is also associated with poor prognosis. Bisphosphonates are currently the mainstay for treating bone metastases in patients with lung cancer, with proven beneficial effects on prevention and delay of skeletal complications. Their role in preventing the development of skeletal metastases, their anti-tumoral properties and their effect on survival remain to be elucidated. Other bone-targeted therapies are being investigated in phase II and III clinical trials and might expand the therapeutic arsenal in the near future.Keywords
This publication has 31 references indexed in Scilit:
- Osteoclast‐targeting small molecules for the treatment of neoplastic bone metastasesCancer Science, 2009
- A Step in the Journey of Denosumab From Bone-Targeted Therapy to Seed- and Soil-Targeted TherapyJournal of Clinical Oncology, 2009
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast ActivityJournal of Thoracic Oncology, 2008
- Skeletal metastases in non-small cell lung cancer: A retrospective studyLung Cancer, 2007
- Impact of Skeletal Complications on Total Medical Care Costs among Patients with Bone Metastases of Lung CancerJournal of Thoracic Oncology, 2006
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005
- Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell linesLung Cancer, 2005
- F-18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost-Effectiveness, and Impact on Patient ManagementJournal of Bone and Mineral Research, 2003
- Palliative therapy for lung cancerSeminars in Surgical Oncology, 2003